Insulin doses requirements in patients with type 1 diabetes using glargine U300 or degludec in routine clinical practice

• Published in: Journal of investigative medicine 2021-06, Vol.69 (5), p.983-988
• Main Authors: Carral San Laureano, Florentino, Tomé Fernández-Ladreda, Mariana, Jiménez Millán, Ana Isabel, García Calzado, Concepción, Ayala Ortega, María del Carmen
• Format: Article
• Language: English
• Subjects: Adult; Blood Glucose; Carbohydrates; Clinical medicine; Creatinine; Diabetes; Diabetes Mellitus, Type 1 - drug therapy; Diabetic retinopathy; Education; Endocrinology; Female; Gender; Glucose monitoring; Glycated Hemoglobin A; Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents - administration & dosage; Insulin; Insulin Glargine - administration & dosage; Insulin, Long-Acting - administration & dosage; Male; Males; Metabolism; Middle Aged; Mortality; Original Research; Regression analysis; Retrospective Studies; Variables; Young Adult
• ISSN: 1081-5589; 1708-8267
• DOI: 10.1136/jim-2020-001633

There are not many real-world studies evaluating daily insulin doses requirements (DIDR) in patients with type 1 diabetes (T1D) using second-generation basal insulin analogs, and such comparison is necessary. The aim of this study was to compare DIDR in individuals with T1D using glargine 300 UI/mL (IGlar-300) or degludec (IDeg) in real clinical practice. An observational, retrospective study was designed in 412 patients with T1D (males: 52%; median age 37.0±13.4 years, diabetes duration: 18.7±12.3 years) using IDeg and IGla-300 ≥6 months to compare DIDR between groups. Patients using IGla-300 (n=187) were more frequently males (59% vs 45.8%; p=0.004) and had lower glycosylated hemoglobin (HbA1c) (7.6±1.2 vs 8.1%±1.5%; p8%. Patients using IGla-300 and IDeg used similar basal, prandial and total DIDR regardless of metabolic control subgroup. No difference in basal, prandial and total DIDR was observed between patients with T1D using IGla-300 or IDeg during at least 6 months in routine clinical practice.